Eine randomisierte, multizentrische, doppelblinde Phase-lll-Studie zu adjuvantem Nivolumab oder Placebo bei Patienten mit reseziertem Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs.

Drug: Nivolumab;Other: Placebo

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction

- Completed pre-operative chemo radiotherapy followed by surgery

- Diagnosed with residual pathologic disease after being surgically rendered free of
disease with negative margins following complete resection

Exclusion Criteria:

- Diagnosed with cervical esophageal carcinoma

- Diagnosed with Stage IV resectable disease

- Did not receive concurrent chemoradiotherapy prior to surgery

- Participants who have received a live/attenuated vaccine within 30 days of the first
treatment

Other protocol defined Inclusion/exclusion criteria could apply